What is MannKind Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. MannKind's interest expense for the
three
months ended in Dec. 2023 was $ -5.4 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.2 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. MannKind's Operating Income for the
three
months ended in Dec. 2023 was $ 10.6 Mil. MannKind's Interest Expense for the
three
months ended in Dec. 2023 was $ -5.4 Mil.
MannKind's Interest Coverage for the quarter that ended in Dec. 2023 was 1.99.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
MannKind Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.2 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MannKind (NAS:MNKD) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
MannKind's Interest Expense for the
three
months ended in Dec. 2023 was $-5.4 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $10.6 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $252.6 Mil.
MannKind's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Warning Sign:
Ben Graham prefers companies' interest coverage to be at least 5. MannKind Corps earnings cannot cover its interest expense. If the situation continues, the company may have to issue more debt.
MannKind (MannKind) Business Description
Traded in Other Exchanges
Address
1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Executives
| Michael Castagna |
officer: Chief Commercial Officer |
25134 RYE CANYON LOOP, SUITE 300, VALENCIA CA 91355 |
| David Thomson |
officer: VP & Assoc General Counsel |
28903 NORTH AVENUE PAINE, VALENCIA CA 91355 |
| Steven B. Binder |
officer: Chief Financial Officer |
30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362 |
| Burkhard Blank |
officer: EVP Chief Medical Officer |
C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
| Lauren M Sabella |
officer: EVP Chief Operating Officer |
C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502 |
| Sanjay R Singh |
officer: EVP Technical Operations |
1 CASPER STREET, DANBURY CT 06810 |
| Alejandro Galindo |
officer: Chief Commercial Officer |
30930 RUSSELL RANCH RD, STE 300, WESTLAKE VILLAGE CA 91362 |
| Stuart A Tross |
officer: Corp VP, Chief People Officer |
ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
| Anthony C Hooper |
director |
AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799 |
| Jennifer Grancio |
director |
30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA 91362 |
| Christine Mundkur |
director |
|
| Sabrina Kay |
director |
30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362 |
| David M Kendall |
officer: Chief Medical Officer |
30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362 |
| Patrick Mccauley |
officer: Chief Commercial Officer |
30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362 |
| Barton Courtney |
officer: Chief Compliance Officer |
30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362 |
MannKind (MannKind) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MNKD has been successfully added to your 